Glaukos is trading higher as investors react to the company’s recent announcement that Epioxa is now commercially available, adding a new marketed product in corneal care and creating a fresh near-term revenue catalyst. The stock’s upside move appears to reflect expectations that Epioxa uptake, alongside continued iDose TR momentum, could support the company’s 2026 growth narrative.

Epioxa is positioned as an incision-free, oxygen- and light-activated corneal cross-linking therapy for keratoconus, which can broaden Glaukos’ revenue mix beyond glaucoma and into interventional corneal disease. The commercial availability milestone is particularly important because the company previously indicated plans to make Epioxa available in the first quarter of 2026, and the launch signals the transition from approval to monetization.

Beyond Epioxa, sentiment has been supported by FDA approval of a labeling supplement that allows re-administration of iDose TR, which can enable repeat implantations over time and potentially increase lifetime value per patient. Separately, Glaukos has reaffirmed its 2026 net sales guidance of $600 million to $620 million, keeping attention on sustained growth after record 2025 results.

Investors are likely to focus on early Epioxa launch indicators, including distributor channel build, physician adoption, and reimbursement traction. The next major scheduled catalyst is the next earnings report window around May 6, 2026, when the company can update on launch cadence and whether it remains on track with the 2026 revenue outlook.